IVERIC bio NasdaqGS:ISEE Rapport sur les actions Finances de l'entreprise + 9 Analystes
IVERIC bio, Inc.
NasdaqGS:ISEE Rapport sur les actions
Capitalisation boursière : US$5.5b
ISEE Aperçu des actions IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs.
Récompenses Analyse des risques Voir tous les contrôles de risques IVERIC bio, Inc. Concurrents Historique des prix et performances
Résumé des plus hauts, des changements et des baisses de prix pour IVERIC bio Historique des cours de bourse Prix actuel de l'action US$39.95 Plus haut sur 52 semaines US$39.99 Plus bas sur 52 semaines US$9.39 Bêta 1.1 1Variation sur 1 mois 4.91% Variation sur 3 mois 39.10% Variation sur 1 an 236.28% 3Variation sur 3 ans 791.74% Variation sur 5 ans 1,413.26% Évolution depuis l'introduction en bourse 51.90%
Nouvelles et mises à jour récentes
IVERIC bio, Inc. Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy Sep 19
European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy Aug 18
Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy Aug 05
IVERIC bio, Inc. Files Form 15 Jul 23
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from NASDAQ Composite Index Jul 13 IVERIC bio's Common Stock Delisted from NASDAQ Voir plus de mises à jour
IVERIC bio, Inc. Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy Sep 19
European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy Aug 18
Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy Aug 05
IVERIC bio, Inc. Files Form 15 Jul 23
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from NASDAQ Composite Index Jul 13 IVERIC bio's Common Stock Delisted from NASDAQ
Senior VP & COO exercised options and sold US$730k worth of stock Jul 07
Senior VP & COO notifies of intention to sell stock Jun 05
Consensus EPS estimates fall by 12% May 19
Forecast to breakeven in 2025 May 12
Senior VP exercised options and sold US$2.2m worth of stock May 05
Price target increased by 10% to US$35.09 May 01
Forecast to breakeven in 2025 Apr 25
Senior VP notifies of intention to sell stock Apr 24
Senior VP & COO exercised options and sold US$940k worth of stock Apr 06
Consensus revenue estimates fall by 13% Mar 08
Senior VP & COO exercised options and sold US$299k worth of stock Mar 07
No longer forecast to breakeven Mar 03
Senior VP & COO exercised options and sold US$314k worth of stock Feb 24
IVERIC bio, Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Avacincaptad Pegol for the Treatment of Geographic Atrophy Feb 17
Senior VP & COO notifies of intention to sell stock Feb 06
CEO & Director exercised options and sold US$350k worth of stock Jan 05
Iveric Bio Announces the Addition of Pravin U. Dugel to Its Board of Directors Jan 04
Forecast to breakeven in 2025 Dec 31 Iveric Bio, Inc. Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy Dec 21
Senior VP & COO exercised options and sold US$259k worth of stock Dec 15
Senior VP & COO exercised options to buy US$109k worth of stock. Dec 07 IVERIC bio, Inc. has completed a Follow-on Equity Offering in the amount of $300.375 million. Dec 02
President exercised options to buy US$179k worth of stock. Nov 22
IVERIC bio, Inc. Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy Nov 18
Price target increased to US$30.17 Nov 05
Senior VP & COO exercised options and sold US$964k worth of stock Nov 04
IVERIC bio, Inc. Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy Nov 04
IVERIC bio, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Iveric Bio Announces Positive Topline Data from Zimura® Gather2 Phase 3 Clinical Trial in Geographic Atrophy Sep 07
Price target increased to US$26.36 Sep 06
Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate Sep 06
Senior VP & Chief Commercial Officer exercised options and sold US$138k worth of stock Aug 05
IVERIC bio Q2 2022 Earnings Preview Jul 25
IVERIC bio, Inc. to Report Q2, 2022 Results on Jul 26, 2022 Jul 22
Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® At American Society of Retina Specialists Meeting Jul 17
Insider exercised options and sold US$73k worth of stock Jul 06
Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura Jul 05 IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Microcap Value Index
IVERIC bio: A First Take Jun 23
Independent Director recently bought US$241k worth of stock Jun 16
IVERIC bio, Inc. Announces Presentation of Post-Hoc Analysis At Macula Society from Gather1 Clinical Trial of Zimura® in Patients with Geographic Atrophy Jun 11
We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely May 20
Price target increased to US$24.38 Apr 27
IVERIC bio, Inc. Completes Retrospective Review of Choroidal Neovascularization Apr 06
IVERIC bio, Inc., Annual General Meeting, May 12, 2022 Mar 31
Senior VP exercised options and sold US$261k worth of stock Mar 30
Senior VP notifies of intention to sell stock Mar 24
IVERIC bio, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 18
Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy Feb 12
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation Feb 01
IVERIC bio, Inc. Announces in GATHER2, the Company's Phase 3 Clinical Trial Evaluating the Safety and Efficacy of Zimura (Avacincaptad Pegol) for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration Jan 12
CEO & Director exercised options and sold US$882k worth of stock Jan 04
CEO & Director exercised options and sold US$122k worth of stock Dec 15
Insider recently bought US$50k worth of stock Nov 24
IVERIC bio (NASDAQ:ISEE) Is In A Good Position To Deliver On Growth Plans Nov 03
Estimating The Intrinsic Value Of IVERIC bio, Inc. (NASDAQ:ISEE) Sep 28
Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field Sep 16
Price target increased to US$16.50 Aug 19
IVERIC Bio, Inc. Provides Updates on Clinical Trails Jul 15
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation Jul 02
Price target increased to US$14.67 Jun 23
IVERIC bio, Inc. Updates on Its Phase 3 Clinical Trails Zimura Jun 22
IVERIC bio discusses GATHER2 enrollment and retention updates and new GATHER1 post-hoc analyses Jun 18
IVERIC bio EPS misses by $0.04 May 05
We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely Mar 12
New 90-day low: US$5.58 Jan 21
IVERIC bio, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Jan 12
Senior VP & COO exercised options and sold US$81k worth of stock Jan 07
Executive Chairman exercised options and sold US$67k worth of stock Dec 15
New 90-day high: US$6.91 Dec 05
We Think IVERIC bio (NASDAQ:ISEE) Can Afford To Drive Business Growth Nov 27
New 90-day high: US$6.48 Nov 06
IVERIC bio EPS misses by $0.05 Nov 02
IVERIC bio, Inc. to Report Q3, 2020 Results on Nov 02, 2020 Oct 28
New 90-day high: US$6.38 Oct 17
IVERIC bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Program Oct 03
New 90-day high: US$6.29 Sep 21
IVERIC bio, Inc. to Report Q2, 2020 Results on Aug 05, 2020 Jul 31 Rendement pour les actionnaires ISEE US Biotechs US Marché 7D 0.9% 3.7% 5.7% 1Y 236.3% 29.2% 36.9%
Voir le rapport complet des actionnaires
Rendement vs Industrie: ISEE a dépassé le secteur US Biotechs qui a rapporté 29.2 % au cours de l'année écoulée.
Rendement vs marché: ISEE a dépassé le marché US qui a rapporté 36.9 % au cours de l'année écoulée.
Volatilité des prix Is ISEE's price volatile compared to industry and market? ISEE volatility ISEE Average Weekly Movement 5.4% Biotechs Industry Average Movement 9.5% Market Average Movement 6.2% 10% most volatile stocks in US Market 15.3% 10% least volatile stocks in US Market 3.0%
Cours de l'action stable: Le cours de l'action de ISEE a été volatil au cours des 3 derniers mois.
Volatilité au fil du temps: La volatilité hebdomadaire de ISEE a diminué de 13% à 5% au cours de l'année écoulée.
À propos de l'entreprise Afficher plus IVERIC bio, Inc. Résumé des fondamentaux Comment les bénéfices et les revenus de IVERIC bio se comparent-ils à sa capitalisation boursière ? ISEE statistiques fondamentales Capitalisation boursière US$5.51b Bénéfices(TTM) -US$222.90m Recettes(TTM ) n/a
Bénéfices et recettes Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM) ISEE compte de résultat (TTM ) Recettes US$0 Coût des recettes US$136.54m Marge brute -US$136.54m Autres dépenses US$86.37m Les revenus -US$222.90m
Derniers bénéfices déclarés
Mar 31, 2023
Prochaine date de publication des résultats
s/o
Résultat par action (EPS) -1.62 Marge brute 0.00% Marge bénéficiaire nette 0.00% Ratio dettes/capitaux propres 20.3%
Quelles ont été les performances à long terme de ISEE?
Voir les performances historiques et les comparaisons
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
